Hodgkin S Lymphoma clinical trials

Explore recruiting hodgkin s lymphoma clinical trials.

Recruiting hodgkin s lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hodgkin S Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Belgium, Italy, Czechia, Denmark, France, Poland +2 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Spain, Denmark, Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Italy, Spain, Czechia, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Hodgkin S Lymphoma trials by city

Hodgkin S Lymphoma in Toronto Hodgkin S Lymphoma in Vancouver Hodgkin S Lymphoma in Montreal Hodgkin S Lymphoma in Calgary Hodgkin S Lymphoma in Edmonton Hodgkin S Lymphoma in Ottawa Hodgkin S Lymphoma in Winnipeg Hodgkin S Lymphoma in Quebec City Hodgkin S Lymphoma in Hamilton Hodgkin S Lymphoma in Kitchener Hodgkin S Lymphoma in London Hodgkin S Lymphoma in Halifax Hodgkin S Lymphoma in New York Hodgkin S Lymphoma in Los Angeles Hodgkin S Lymphoma in Chicago Hodgkin S Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease